(Reuters) – Swiss drug maker Actelion’s chief executive quashed speculation over its possible interest in purchasing Basilea Pharmaceutica.
“Basilea has developed interesting medications. But the company already has a partner,” Chief Executive Jean-Paul Clozel was quoted as saying in an interview published on Swiss paper Finanz und Wirtschaft’s website on Friday.
“Since we’re interested in active substances and not financial opportunities, it wouldn’t make sense for us to buy Basilea.”
(Reporting by Brenna Hughes Neghaiwi)
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.